INTERNATIONAL MYELOMA SOCIETY
Educational Symposia Series

Santiago, Chile–August 11-12, 2017 (Crowne Plaza) Prague,
Czech Republic–September 29-30, 2017 (Marriott) United
States-TBD–November, 2017

The International Myeloma Society (IMS) is a professional, scientific and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The IMS accomplishes its mission by providing educational forums in the form of conferences, symposia, and workshops conducted around the globe.

The goal for the Educational Symposia Series is to share with local hematologists the state of the art on diagnosis, monitoring and treatment of Plasma Cell malignancies paying special attention to the current practice in the local countries and the opportunities for improvement. Our purpose is also to offer the opportunity for social interaction in order to establish potential collaborations with the invited speakers including the possibility of visiting their institutions or establishing fellowship programs.

The program will include lectures plus roundtable discussions around the most hot and controversial topics. The format of the roundtable will include the counterpoint opinion of the invited speakers with the local hematologists based on both challenging questions and clinical cases.

Local program chair(s) are selected to help to ensure the content will address the needs from the regions/countries in which the programs are held.

**Santiago Program Chairs:**
Guilhermo Conte, MD
Hospital Clinico de la Universidad de Chile
Vania Hungria, MD
Irmandade da Santa Clara de Misericordia de Sao Paulo
Dorotea Fantl
Hospital Italiano de Buenos Aires

**Prague Program Chairs:**
Roman Hajek, MD
University Hospital Ostrava
Ivan Spicka, MD
VHN Charles University Prague
Jiri Minarik, MD
University Hospital, Olomouc
SANTIAGO, CHILE

PRELIMINARY PROGRAM

**Friday, August 11, 2017**

07:45-8:00 Welcome and introduction

08:00-08:30 The myeloma pathogenesis with focus on the immune system
*Ivan Borrelo*

08:30-9:00 Genetics in MM patients
*Rafael Fonseca*

09:00-09:30 What are the optimal Imaging Techniques in MM? MRI, CT-scan and PET?
*Marivi Mateos*

09:30-10:00 Coffee

10:00-10:30 How to perform an appropriate protein screening and decisions on follow-up?
*Joan Blade*

10:30-11:00 Minimal residual Disease. How and when to do it?
*Jesús San Miguel*

11:00-12:00 **Roundtable:** How to do a correct diagnosis and follow-up, including the new diagnostic and response criteria
*Moderator: Jesús San Miguel: 2-3 clinical cases*
*Discussants: G. Conte, D. Fantl, J. Navarro, J. Blade, R. Fonseca*

12:00-13:00 Lunch

13:00-13:30 MGUS & Smouldering Myeloma. How to predict outcome & “To treat or not to treat”
*Marivi Mateos*

13:30-15:00 How I treat newly diagnosed transplant candidate MM patients
*Sergio Giralt (30’).*
**Roundtable** on 6 controversial questions with emphasis in local practice (60’)
*Moderator: Rafael Fonseca*
*Discussants: D. Gómez-Almaguer, A. Maiolino, N. Schutz, J Berdeja, S. Giralt, J. San Miguel*

1. Best induction
2. Early vs. late transplant
3. One or two
4. Consolidation
5. Maintenance
6. Allotransplant
Friday, August 11, 2017 (continued)

15:00-15:30 Coffee

15:30-17:00 How I treat newly diagnosed elderly patients?
    Ruben Niesvizky (30’)
    **Roundtable** on 5 controversial questions with emphasis in local practice (60’)
    **Moderator:** Marivi Mateos
    **Discussants:** V. Hungria, JL Lopez, E. Riva, S. Giralt, R. Fonseca, R. Niesvizky
    1. Optimal combinations
    2. Fixed versus continuous therapy
    3. Do we need alkylators?
    4. High risk
    5. Frailty scales

Saturday, August 12, 2017

8:00-9:30 How to make the right choices in the relapsed patient
    Enrique Ocio
    **Roundtable** on **5 clinical cases** with emphasis in local practice (60’)
    **Moderator:** Jesus San Miguel
    **Discussants:** T. Anguita, E. Crusoe, A. Karduss, E. Ocio, R Niesvizky, J Berdeja
    1. Biological relapse versus aggressive relapse
    2. Early and late relapse and ASCT
    3. Triplet versus doublets: is it cost-effective?
    4. Optimal sequence for new agents
    5. Allotransplant

9:30-10:00 Amyloidosis: “Under-diagnosed disorder”
    Joan Bladé

10:00-10:30 Waldenström Macroglobulinemia
    Enrique Ocio

10:30-11:00 Coffee

11:00-11:30 Treatment of Disease Complications
    Jesus Berdeja

11:30-12:15 Keynote lecture: Present and future of MM.
    Nikhil Munshi

12:15 Lunch